Neurescue

Neurescue is a pioneering medical device company addressing the critical unmet need in non-shockable cardiac arrest, where 81% of cases present and only 4% survive with current standard of care. The company has developed and achieved CE Mark (Class III) for the first computer-aided aortic balloon catheter designed to rapidly increase cerebral and coronary perfusion during CPR, aiming to achieve return of spontaneous circulation or conversion to a shockable rhythm. Founded in 2017 and based in Copenhagen, Neurescue is a private, likely pre-revenue company that has secured European innovation grants and is positioned to disrupt emergency cardiovascular resuscitation.

Computer-aided aortic balloon occlusion catheter system with intelligent safety feedback and pressure-controlled inflation, designed to supercharge blood flow to the heart and brain during cardiac arrest resuscitation.

Neurescue appears to be first-to-market with a device specifically approved for non-shockable cardiac arrest. Direct competitors are not yet evident, but the space may attract large cardiovascular device companies. The primary competition is the entrenched, ineffective standard of care (CPR alone).